United Therapeutics Corp (UTHR)
262.40
+4.27
(+1.65%)
USD |
NASDAQ |
May 03, 16:00
262.33
-0.07
(-0.03%)
After-Hours: 20:00
United Therapeutics Net Income (Quarterly): 306.60M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 306.60M |
| December 31, 2023 | 217.10M |
| September 30, 2023 | 267.60M |
| June 30, 2023 | 259.20M |
| March 31, 2023 | 240.90M |
| December 31, 2022 | 132.10M |
| September 30, 2022 | 239.30M |
| June 30, 2022 | 116.00M |
| March 31, 2022 | 239.90M |
| December 31, 2021 | 112.20M |
| September 30, 2021 | 162.70M |
| June 30, 2021 | 172.60M |
| March 31, 2021 | 28.30M |
| December 31, 2020 | 98.80M |
| September 30, 2020 | 171.20M |
| June 30, 2020 | 107.10M |
| March 31, 2020 | 137.70M |
| December 31, 2019 | 52.60M |
| September 30, 2019 | 132.40M |
| June 30, 2019 | 205.10M |
| March 31, 2019 | -494.60M |
| December 31, 2018 | 65.30M |
| September 30, 2018 | 106.50M |
| June 30, 2018 | 172.90M |
| March 31, 2018 | 244.50M |
| Date | Value |
|---|---|
| December 31, 2017 | 19.00M |
| September 30, 2017 | 276.30M |
| June 30, 2017 | -56.00M |
| March 31, 2017 | 178.60M |
| December 31, 2016 | 110.30M |
| September 30, 2016 | 161.80M |
| June 30, 2016 | 206.10M |
| March 31, 2016 | 235.50M |
| December 31, 2015 | 104.60M |
| September 30, 2015 | 464.40M |
| June 30, 2015 | 99.20M |
| March 31, 2015 | -16.60M |
| December 31, 2014 | 115.96M |
| September 30, 2014 | -25.24M |
| June 30, 2014 | 111.85M |
| March 31, 2014 | 137.52M |
| December 31, 2013 | -30.31M |
| September 30, 2013 | 62.68M |
| June 30, 2013 | 79.86M |
| March 31, 2013 | 62.32M |
| December 31, 2012 | 83.26M |
| September 30, 2012 | 78.11M |
| June 30, 2012 | 72.32M |
| March 31, 2012 | 70.76M |
| December 31, 2011 | 43.19M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
28.30M
Minimum
Mar 2021
306.60M
Maximum
Mar 2024
169.97M
Average
166.95M
Median
Net Income (Quarterly) Benchmarks
| Liquidia Corp | -27.45M |
| Esperion Therapeutics Inc | -56.34M |
| Vertex Pharmaceuticals Inc | 968.80M |
| Heron Therapeutics Inc | -10.72M |
| Aldeyra Therapeutics Inc | -4.753M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 677.70M |
| Total Expenses (Quarterly) | 321.40M |
| EPS Diluted (Quarterly) | 6.17 |
| Enterprise Value | 9.534B |
| Gross Profit Margin (Quarterly) | 89.24% |
| Profit Margin (Quarterly) | 45.24% |
| Earnings Yield | 8.06% |
| Operating Earnings Yield | 9.63% |
| Normalized Earnings Yield | 8.060 |